Erratum: Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome (Journal of Clinical Endocrinology and Metabolism (2015) 100, 4 (1485-1493) DOI: 10.1210/jc.2014-2544);Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1485-1493

  Li, Minyan ^a   Yang, Mengliu ^a   Zhou, Xiaoxin ^a   Fang, Xia ^a   Hu, Wenjing ^a   Zhu, Wei ^a   Wang, Cong ^a   Liu, Dongfang ^a   Li, Shengbing ^a   Liu, Hua ^b   Yang, Gangyi ^a   Li, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; INSULIN; IRISIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROTEIN PRECURSOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FIBRONECTIN; FNDC5 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN;

ADULT; ANDROGEN INDEX; ARTICLE; BODY MASS; CHINA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; DRUG EFFECT; ENDOCRINE FUNCTION TEST; EUGLYCEMIC HYPERINSULINEMIC CLAMP; FEMALE; GASTROINTESTINAL TOXICITY; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; INTRAABDOMINAL FAT; IRISIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OUTPATIENT; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; WAIST HIP RATIO; BLOOD; COMPLICATION; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; YOUNG ADULT;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FIBRONECTINS; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS, LDL; METFORMIN; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; UP-REGULATION; YOUNG ADULT;

EID: 84927634526     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2609     Document Type: Erratum

References (26)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800.
2. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946-951.
3. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. 2006;30:13-17.
4. Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011;96:E480-E484.
5. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2008;69:634-641.
6. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl). 2007;85:1413-1420.
7. Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ. Retinolbinding protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes Care. 2008;31:1427-1432.
8. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes. 2010;59:3023-3031.
9. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-β-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468.
10. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100:96-101.
11. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98:E769-E778.
12. Ebert T, Stepan H, Schrey S, et al. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine. 2014;65:153-158.
13. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61:1725-1738.
14. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index. Peptides. 2013;39:125-130.
15. Timmons JA, Baar K, Davidsen PK, Atherton PJ. Is irisin a human exercise gene? Nature. 2012;488:E9-E10; discussion E10-E11.
16. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:365-369.
17. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-47.
18. Jia Y, Yuan L, Hu W, et al. Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans. J Intern Med. 2014;275:522-533.
19. Yang M, Liu R, Li S, et al. Zinc-β2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care. 2013;36:1074-1082.
20. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191-2192.
21. Kurdiova T, Balaz M, Vician M, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014;592:1091-1107.
22. Spiegelman BM. Banting Lecture 2012: Regulation of adipogenesis: toward new therapeutics for metabolic disease. Diabetes. 2013;62:1774-1782.
23. Park KH, Zaichenko L, Peter P, et al. Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism. 2014;63:233-241.
24. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86:658-663.
25. Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. HumReprod Update. 2014;20:656-669.
26. Zheng J, Shan PF, Gu W. The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. J Endocrinol Invest. 2013;36:797-802.